Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08), Zacks reports. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD traded down $0.05 during mid-day trading on Thursday, reaching $1.66. 1,512,838 shares of the company traded hands, compared to its average volume of 3,459,469. Ironwood Pharmaceuticals has a fifty-two week low of $1.59 and a fifty-two week high of $15.24. The firm has a market cap of $265.17 million, a PE ratio of -55.50 and a beta of 0.29. The stock has a fifty day simple moving average of $3.26 and a 200-day simple moving average of $3.87.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 192,381 shares of company stock worth $338,591 over the last quarter. 12.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Craig Hallum decreased their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. JMP Securities dropped their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.60.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.